US Stock MarketDetailed Quotes
CARA Cara Therapeutics
- 0.759
- +0.007+0.89%
Close May 1 16:00 ET
41.47MMarket Cap-346P/E (TTM)
0.777High0.723Low190.44KVolume0.756Open0.752Pre Close142.56KTurnover0.48%Turnover RatioLossP/E (Static)54.67MShares4.67052wk High0.73P/B29.86MFloat Cap0.50052wk Low--Dividend TTM39.37MShs Float29.647Historical High--Div YieldTTM7.25%Amplitude0.500Historical Low0.748Avg Price1Lot Size
About Cara Therapeutics Company
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Company Profile
SymbolCARA
Company NameCara Therapeutics
Listing DateJan 31, 2014
Issue Price11.00
Founded2004
CEOMr. Christopher A. Posner
MarketNASDAQ
Employees55
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address400 Atlantic Street,Suite 500
CityStamford
ProvinceConnecticut
CountryUnited States of America
Zip Code06901
Phone1-203-406-3700
Company Executives
- Name
- Position
- Salary
- Christopher A. Posner
- President, Chief Executive Officer and Director
- 2.92M
- Scott M. Terrillion
- General Counsel, Secretary and Chief Compliance Officer
- 1.39M
- Ryan D. Maynard
- Chief Financial Officer and Principal Accounting Officer
- 1.24M
- Martin A. Vogelbaum
- Chairman of the Board
- 519.99K
- Dr. Lisa von Moltke, M.D.
- Independent Director
- 254.99K
- Helen M. Boudreau, M.B.A.
- Independent Director
- 376.01K
- Dr. Susan Shiff, M.B.A.,PhD
- Independent Director
- 262.49K
- Dr. Jeffrey L. Ives, PhD
- Independent Director
- 272.49K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg